# Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

> **NCT06090318** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Rain Oncology Inc**

## Conditions studied

- Advanced Solid Tumor
- CDKN2A
- NSCLC
- Urothelial Carcinoma Bladder
- Melanoma
- Pancreas Adenocarcinoma
- HNSCC
- Renal Cell Carcinoma
- Mesothelioma
- Gastric Cancer

## Interventions

- **DRUG:** Milademetan
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT06090318
- **Lead sponsor:** Rain Oncology Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-05-19
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2023-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06090318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06090318, "Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06090318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*